Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3K alpha Inhibitor TAK-117 in Preclinical Bladder Cancer Models

Hernandez-Prat, A; Rodriguez-Vida, A; Juanpere-Rodero, N; Arpi, O; Menendez, S; Soria-Jimenez, L; Martinez, A; Iarchouk, N; Rojo, F; Albanell, J; Brake, R; Rovira, A; Bellmunt, J

Bellmunt, J (reprint author), IMIM Hosp del Mar Res Inst, PRBB Bldg,Doctor Aiguader 88,1st Floor, Barcelona 08003, Spain.

MOLECULAR CANCER RESEARCH, 2019; 17 (9): 1931

Abstract

Advanced bladder cancer is associated with a poor prognosis and limited treatment options. The PI3K/AKT/mTOR pathway is frequently activated in this d......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索